Cervarix Receives First Approval

UK-based drugmaker GlaxoSmithKline (GSK)'s cervical cancer vaccine Cervarix has been approved in Australia, its first major market. This news is a bright note for GSK after the company recently experienced a sharp fall in share prices due to concerns over the safety of blockbuster diabetes drug Avandia.

To read the full article, please choose one of the following options: